Public Sector Pension Investment Board Increases Stake in Collegium Pharmaceutical, Inc. $COLL

Public Sector Pension Investment Board lifted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 11.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,899 shares of the specialty pharmaceutical company’s stock after acquiring an additional 13,104 shares during the quarter. Public Sector Pension Investment Board owned 0.39% of Collegium Pharmaceutical worth $4,300,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Federated Hermes Inc. increased its position in Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the period. CWM LLC lifted its position in shares of Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares during the period. Hantz Financial Services Inc. boosted its stake in shares of Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 993 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 2,294 shares during the period.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $4,991,038.21. This represents a 14.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This trade represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on COLL. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Barclays decreased their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. HC Wainwright reissued a “buy” rating and set a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a research report on Friday, January 9th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $53.40.

Collegium Pharmaceutical Trading Down 0.2%

Collegium Pharmaceutical stock opened at $45.18 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. The stock has a market cap of $1.43 billion, a PE ratio of 28.06 and a beta of 0.64. The stock has a 50-day moving average of $47.04 and a two-hundred day moving average of $41.54. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $50.79.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.